Carnaculin + V-Omin

Carnaculin + V-Omin is a combination therapy developed by AJU Pharm Co., Ltd. for the treatment of non-proliferative diabetic retinopathy (NPDR). Carnaculin contains kallidinogenase (pancreatic kininogenase), a proteolytic enzyme that cleaves kininogen to produce kinins, which promote vasodilation and improve retinal microcirculation. V-Omin is a vitamin B complex featuring benfotiamine, a lipid-soluble thiamine derivative that activates the enzyme transketolase. This activation helps divert excess glucose metabolites into the pentose phosphate pathway, thereby inhibiting the formation of advanced glycation end-products (AGEs) and reducing oxidative stress associated with diabetic microvascular damage. The combination is evaluated for its ability to reduce hard exudates and stabilize retinal health in NPDR patients.

Brand names

CarnaculinV-Omin

Other names

kallidinogenase + benfotiamineB55R1 + B55R2-AJU Pharm Co., Ltd.-non-proliferative diabetic retinopathy